Pancreatic cancer will account for about 3% of all cancer diagnoses in the U.S. this year. However, more than 50,000 Americans will die of the disease, making it the third most common cause of cancer-related mortality, according to Andrew Rakeman, PhD, vice president for research at Lustgarten Foundation. Read more . . .
Cellular therapies will play a key role in pancreatic cancer management despite challenges thus far in applying these treatments to solid tumors, according to a panel discussion during the virtual Alliance for Cancer Gene Therapy Summit.